DNAprint Genomics (DNAG)

[dgplexus]

"frogdreaming,"

You claimed that "distributors" (plural) had dropped DNAPrint Genomics' products due to "lack of sales." You provided only one case to support your claim, and that case does NOT support your claim, as Sam's rebuttal makes perfectly clear. I await your explanation, apology, retraction, or whatever. Silence on this is not appropriate.

Also, you made clearly false statements regarding the last 8K filing. Silence on that is not appropriate, either.

You claimed (in a message that has since been deleted) the last 8K says "They explained how they had abandoned all of the licenses they were working on and allowed them to default to their owners. They explained how they could not obtain financing and had given up on the attempt to spin off a pharmaceutical division. (A moot point given that they had already defaulted on the licenses that were the foundation of any pharmaceutical effort.)"

That is blatantly false!

Here is the last 8K. It is quite simple and brief:
http://www.sec.gov/Archives/edgar/data/1127354/000111650208000616/dna8k.htm

Other filings listed here, for those who haven't seen them lately:
http://www.sec.gov/cgi-bin/browse-edgar?company=dnaprint&CIK=&State=&SIC=&action=getcompany

The last 8K certainly did not state what you claim.

DNAPrint Genomics Pipeline -- compare to contents of the last 8K filing, and what "frogdreaming" claims:
http://www.dnaprint.com/welcome/pipeline/
( And don't forget DNAWitness.
http://dnaprint.humid.e-symposium.com/dnawitness/dnawtest.html )

DNAPrint Genomics has _a_lot_ more going for it, than you insinuate. Spreading misinformation to create a false impression about a stock, is unethical and illegal.

DNAPrint Genomics' performance (quite distinct from the share price) has been admirable. They've achieved quite a lot, even wide recognition in the press, and now more than just a few distributors, and broadly acknowledged cutting-edge technology (that has already been field-proven,) with a notably lean burn rate, on their funding. I'm proud to be a major shareholder, and I'm proud of DNAPrint Genomics. I can't think of a better risk:return investment.